PB2198: TRIAL IN PROGRESS: AN OPEN-LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL-895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF)

oleh: Francesca Palandri, Stefanie Gröpper, Michael Loschi, Marcelo Bellesso, Sebastian Grosicki, Pilar Giraldo, Claire Harrison, Tracy Clevenger, Nikki Stuart, Hope Qamoos, Gregory Vosganian, Wayne P. Rothbaum, Srdan Verstovsek, Pankit Vachhani